← 返回

靶向癌症干细胞的免疫治疗:抗癌免疫治疗的新策略

英文原题:Targeted immunotherapy to cancer stem cells: A novel strategy of anticancer immunotherapy.

查看英文原题

Targeted immunotherapy to cancer stem cells: A novel strategy of anticancer immunotherapy.

PubMed 2024/02/28(内容时间) Crit Rev Oncol Hematol Q1 · IF 6.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

癌症是危害人类健康的重大疾病。癌症耐药和复发是导致癌症治疗失败的两个主要原因。癌症干细胞(CSCs)是肿瘤细胞中的一小部分,负责肿瘤发生、转移、复发以及对传统抗癌疗法的耐药性。因此,CSCs被认为是癌症复发、转移和耐药性的根源。新型抗癌策略需要面对这一新挑战,并探索其针对CSCs的疗效。近年来,免疫疗法在癌症治疗中取得了快速进展,其针对CSCs的潜力也是一个有趣的研究领域。同时,免疫治疗策略是靶向CSCs的新型治疗方式,具有前景广阔的结果。在这篇综述中,我们总结了在临床前和临床研究中,通过多种免疫治疗策略如单克隆抗体(mAb)、肿瘤疫苗、免疫检查点抑制剂和CAR-T 细胞靶向CSCs的情况。这篇综述为这些免疫治疗方法在未来潜在抗肿瘤治疗中的应用提供了新的见解。

展开英文摘要原文

Cancer is a major disease that endangers human health. Cancer drug resistance and relapse are the two main causes contributing to cancer treatment failure. Cancer stem cells (CSCs) are a small fraction of tumor cells that are responsible for tumorigenesis, metastasis, relapse, and resistance to conventional anticancer therapies.

Therefore, CSCs are considered to be the root of cancer recurrence, metastasis, and drug resistance. Novel anticancer strategies need to face this new challenge and explore their efficacy against CSCs. Recently, immunotherapy has made rapid advances in cancer treatment, and its potential against CSCs is also an interesting area of research. Meanwhile, immunotherapy strategies are novel therapeutic modalities with promising results in targeting CSCs.

In this review, we summarize the targeting of CSCs by various immunotherapy strategies such as monoclonal antibodies(mAb), tumor vaccines, immune checkpoint inhibitors, and chimeric antigen receptor-T cells(CAR-T) in pre-clinical and clinical studies. This review provides new insights into the application of these immunotherapeutic approaches to potential anti-tumor therapies in the future.

论文信息

作者
Yi SY、Wei MZ、Zhao L
第一作者单位
Department of Oncology of the Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zheng Zhou, Henan Province 450007, China. Electronic address: yisy2001@zzu.edu.cn.China
通讯作者单位
Department of Oncology of the Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zheng Zhou, Henan Province 450007, China. Electronic address: zhaoling2011@163.com.China
文献类型
综述
期刊
Critical reviews in oncology/hematology2024 Apr
原文标识
PubMed 38428702 · DOI 10.1016/j.critrevonc.2024.104313